Therefore, targeting VEGFR-2 in colon cancer treatment isan important strategy for reducing tumor vascularization and inhibitingtumor growth.−, , , , ,  As mentioned in Figure , the compounds were designed based on sorafenib, a VEGFR-2inhibitor. The gene discussed is KDR; the disease is malignant colon neoplasm.